How long does a box of Ivonib/Tosovo usually last?

Ivosidenib (Ivosidenib) is a long-term oral targeted drug. In actual treatment, it generally needs to be taken regularly to maintain stable drug concentration and efficacy in the body. According to the common dosage method, it is recommended to take 500mg orally daily, which can be taken with food or on an empty stomach. Therefore, how long a box of medicine can be taken depends mainly on the specifications used by patients with (acute myeloid leukemia, cholangiocarcinoma, myelodysplastic syndrome) and the total daily dose.

If we take the common 250mg strength as an example, a daily dose of 500mg requires two tablets, so a box of 60 tablets can theoretically be used for about 30 days. If the patient is using other specifications, the corresponding dosage can also be converted. Since ivonib emphasizes "continuous daily use", treatment time is often accumulated in monthly units. Therefore, patients need to use monthly use as a basis when planning their medication budget and purchase cycle.

There is no fixed end time for the treatment course of ivonib, and it is generally continued until the disease progresses or toxic reactions that cannot be continued occur. This kind of "disease-oriented" medication is different from traditional chemotherapy and is more like long-term maintenance treatment. Therefore, patients need to insist on regular follow-up visits and monitor metabolic indicators and organ functions.

During the medication period, patients need to take it at the same time every day to avoid missing doses or stopping the medication at will. If you have difficulty taking medication due to physical discomfort, gastrointestinal reactions, etc., you should report it to your doctor in time, and a professional will evaluate whether you need to adjust the dosage or postpone treatment. Some patients will experience changes in metabolism or liver function indicators during long-term medication. This does not mean that the medication must be stopped immediately, but that careful management is required based on monitoring.

In terms of economics, since ivonib has not yet been included in medical insurance and its price is relatively high, patients need to plan their long-term medication budget in advance. They can also combine it with overseas generic drugs as an affordable alternative version to ensure continuity of treatment.

Reference: https://www.tibsovo.com/